Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology. Read the full article: Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease ... Show More
Sep 9
The future of Alzheimer’s disease: blood biomarkers, brain imaging, and screening the cognitively unimpaired
What will Alzheimer’s disease diagnosis look like in 5–10 years? In this episode of In Conversation With…, Laura Hart is joined by the authors behind The Lancet Neurology Series on Future Directions in Alzheimer’s Disease and Related Disorders: Clifford Jack (Mayo Clinic), Charlo ... Show More
28m 49s
Jul 15
Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis
In this episode, Heather Brown, Senior Editor at The Lancet Neurology, chats with Jan Lünemann (University of British Columbia, Canada) and Christian Münz (University of Zürich, Switzerland) about their Rapid Review on Epstein-Barr virus (EBV) and multiple sclerosis (MS). EBV, a ... Show More
15m 45s
Aug 2023
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
<p>In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.<br /> <br /> <stron ... Show More
28m 48s
Oct 2018
#043 Dr. Dale Bredesen on Preventing and Reversing Alzheimer's Disease
<p><strong>Dale E. Bredesen</strong></p> <p>Dale E. Bredesen, M.D., is a professor of neurology at the Easton Laboratories for Neurodegenerative Disease Research at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).</p> <p>Dr. Bredesen's labo ... Show More
1h 14m